




UNCOMMON GYNECOLOGIC CANCERS



Edited by

Marcela G. del Carmen

Robert H. Young, John O. Schorge, Michael J. Birrer

WILEY Blackwell

CONTENTS

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Preface](#)

[Part 1: General Principles](#)

[Chapter 1: Molecular Targets in Gynecologic Cancers](#)

[Introduction](#)

[Phosphoinositol 3-kinase \(PI3K\) pathway](#)

[Mitogen-activated protein kinase \(MAPK\) pathway](#)

[Human epidermal growth factor receptor 2 \(HER2\)](#)

[Vascular endothelial growth factor \(VEGF\)](#)

[Poly \(adenosine\) diphosphate \[ADP\]-ribose polymerase \(PARP\)](#)

[References](#)

[Chapter 2: Imaging of Rare Gynecologic Tumors](#)

[Imaging guidelines](#)

[Imaging of uncommon ovarian malignancies](#)

[Imaging of uncommon uterine and endometrial malignancies](#)

[Imaging of uncommon cervical malignancies](#)

[Imaging of uncommon vaginal and vulvar malignancies](#)

[Conclusion](#)

[References](#)

Chapter 3: Pathology Overview of Rare Gynecologic Tumors

Ovary

The Uterine Corpus

Uterine Cervix

Vagina and Vulva

Fallopian Tube

Peritoneum

References

Part 2: Rare Ovarian Cancers

Chapter 4: Ovarian Clear Cell Carcinoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Future directions

Surveillance

Conclusions

References

Chapter 5: Mucinous Epithelial Ovarian Cancer

Introduction

Epidemiology

Pathology

Pathogenesis

[Clinical presentation](#)
[Pretreatment evaluation](#)
[Prognostic factors](#)
[Treatment](#)
[Surveillance](#)
[Conclusions](#)
[References](#)

[Chapter 6: Pseudomyxoma Peritonei](#)

[Introduction](#)
[Epidemiology](#)
[Pathology](#)
[Pathogenesis](#)
[Clinical Presentation](#)
[Pretreatment Evaluation](#)
[Treatment](#)
[Surveillance](#)
[Conclusions](#)
[References](#)

[Chapter 7: Squamous Cell Carcinoma of the Ovary](#)

[Introduction](#)
[Epidemiology](#)
[Pathology](#)
[Pathogenesis](#)
[Clinical presentation](#)
[Pretreatment evaluation](#)
[Treatment](#)
[Survival](#)
[Surgical management](#)

[Fertility-sparing/conservative surgery.](#)

[Chemotherapy.](#)

[Radiation](#)

[Surveillance](#)

[Conclusions](#)

[References](#)

[Chapter 8: Endometriosis-Associated Ovarian Cancer](#)

[Introduction](#)

[Epidemiology.](#)

[Pathology.](#)

[Pathogenesis](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Treatment](#)

[Surveillance](#)

[Conclusions](#)

[References](#)

[Chapter 9: Carcinosarcoma of the Ovary.](#)

[Introduction](#)

[Pathology.](#)

[Pathogenesis](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Prognostic factors](#)

[Treatment](#)

[Surveillance](#)

[Conclusions](#)

[References](#)

Chapter 10: Malignant Germ Cell Tumors of the Ovary.

Introduction

Epidemiology

Pathology

Immature teratoma

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 11: Malignant Sex Cord-Stromal Tumors of the Ovary.

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 12: Small Cell and Neuroendocrine Cancers of the Ovary.

[Introduction](#)

[Small cell carcinoma](#)

[NSCNEC of the ovary](#)

[Conclusions](#)

[References](#)

[Chapter 13: Carcinoid Tumors of the Ovary](#)

[Introduction](#)

[Epidemiology](#)

[Pathology](#)

[Pathogenesis](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Treatment](#)

[Surveillance](#)

[References](#)

[Part 3: Rare Uterine Cancers](#)

[Chapter 14: Uterine Carcinosarcoma](#)

[Epidemiology and presentation](#)

[Pathology](#)

[Pathogenesis](#)

[Surgical treatment](#)

[Adjuvant therapy](#)

[Choice of chemotherapy](#)

[What is the role of RT?](#)

[Treatment for recurrent disease](#)

[Prognosis](#)

[Surveillance](#)

[Conclusions](#)

References

Chapter 15: Uterine Leiomyosarcoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 16: Mucinous Tumors of the Uterine Corpus

Introduction

Epidemiology

Pathology

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 17: Uterine Clear Cell Carcinoma

Introduction

Epidemiology

Pathology

Pathogenesis

[Clinical presentation](#)
[Pretreatment evaluation](#)
[Treatment](#)
[Surveillance](#)
[Conclusions](#)
[References](#)

[Chapter 18: Updates on the Management of Uterine Serous Carcinoma](#)

[Introduction](#)
[Epidemiology](#)
[Pathology](#)
[Pathogenesis](#)
[Clinical presentation](#)
[Pretreatment evaluation](#)
[Treatment](#)
[Surveillance](#)
[Conclusions](#)
[References](#)

[Chapter 19: Endometrial Stromal Sarcomas](#)

[Introduction](#)
[Epidemiology](#)
[Pathology](#)
[Pathogenesis](#)
[Clinical presentation](#)
[Pretreatment evaluation](#)
[Prognostic factors](#)
[Treatment](#)
[Surveillance](#)

[Conclusions](#)

[References](#)

[Part 4: Rare Cancers of the Cervix, Vulva and Vagina](#)

[Chapter 20 : Small Cell Neuroendocrine Carcinoma of the Cervix](#)

[Introduction](#)

[Epidemiology](#)

[Pathology](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Prognostic factors](#)

[Treatment](#)

[Conclusions](#)

[References](#)

[Chapter 21: Primary Malignant Melanoma of the Vagina and Vulva](#)

[Introduction](#)

[Epidemiology](#)

[Pathology](#)

[Pathogenesis](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Treatment](#)

[Surveillance](#)

[Prognosis](#)

[Conclusions](#)

[References](#)

[Chapter 22 : Sarcomas of the Vulva and Vagina](#)

[Introduction](#)

[Epidemiology](#)

[Pathology/pathogenesis](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Treatment](#)

[Surveillance](#)

[Conclusions](#)

[References](#)

[Chapter 23: Gestational Trophoblastic Disease](#)

[Introduction](#)

[Epidemiology](#)

[Pathogenesis](#)

[Pathology](#)

[Clinical presentation](#)

[Pretreatment evaluation](#)

[Treatment](#)

[Surveillance](#)

[Conclusions](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 04

[Table 4.1 Prognostic Factors of Ovarian Clear Cell Carcinomas](#)

[Table 4.2 International Federation of Gynecology and Obstetrics \(FIGO\) surgical staging system for ovarian](#)

[cancer](#)

Chapter 06

[Table 6.1 Survival after surgical cytoreduction for pseudomyxoma peritonei \(PMP\).](#)

[Table 6.2 Selected studies of cytoreductive surgery and intraperitoneal \(IP\) chemotherapy for mucinous appendiceal tumors with peritoneal dissemination](#)

Chapter 07

[Table 7.1 List of pathologies that have been found at the time of diagnosis of ovarian squamous cell carcinoma of the ovary.](#)

[Table 7.2 Sensitivity, Specificity, and Diagnostic Efficiency of Tumor Markers and Clinical Characteristics.](#)

[Table 7.3 Ovarian cancer surveillance recommendations.](#)

Chapter 08

[Table 8.1 Cohort studies evaluating cancer risk in patients with endometriosis](#)

[Table 8.2 Case-control studies evaluating cancer risk in patients with endometriosis](#)

[Table 8.3 Critical molecular events in ovarian clear cell carcinoma arising from endometriosis](#)

Chapter 09

[Table 9.1 Retrospective studies reporting effect of debulking surgery on survival in OCS](#)

[Table 9.2 Summary of chemotherapy studies in OCS](#)

[Table 9.3 Genes/receptors overexpressed in OCS](#)

Chapter 10

[Table 10.1 2003 World Health Organization histologic classification of malignant ovarian germ cell tumors](#)

[Table 10.2 Bleomycin, etoposide, and cisplatin regimen](#)

Chapter 12

[Table 12.1 WHO histologic classification of ovarian tumors](#)

[Table 12.2 Special stains and immunohistochemistry](#)

[Table 12.3 Drug target enrichment analyses and potential targeted therapies](#)

Chapter 14

[Table 14.1 Revised FIGO 2009 staging for uterine carcinosarcomas](#)

Chapter 15

[Table 15.1 FIGO 2009 staging for uterine sarcomas](#)

[Table 15.2 Active chemotherapy agents in the treatment of metastatic or recurrent leiomyosarcoma](#)

Chapter 16

[Table 16.1 Endometrial carcinoma histologic subtypes](#)

[Table 16.2 Studies of mucinous adenocarcinoma of the endometrium](#)

Chapter 19

[Table 19.1 FIGO 2009 staging for uterine sarcomas](#)

[Table 19.2 Treatment strategies for patients with ESS considered for hormonal treatment](#)

Chapter 20

[Table 20.1 Immunohistochemistry markers associated with small cell neuroendocrine carcinoma](#)

[Table 20.2 Etoposide/cisplatin chemotherapy regimen](#)

Chapter 21

[Table 21.1a TNM staging system for vulvar cancer](#)

[Table 21.1b](#)

[Table 21.2a TNM staging system for vaginal cancer](#)

[Table 21.2b](#)

Chapter 22

[Table 22.1 Vulvar sarcomas and recommended treatment](#)

Chapter 23

[Table 23.1 World Health Organization classification of gestational trophoblastic disease.](#)

[Table 23.2 Gestational trophoblastic disease FIGO staging system](#)

List of Illustrations

Chapter 01

[Figure 1.1 PI3K signaling cascade. Schematic showing the PI3K/AKT/mTOR and MAPK pathways and the current agents in development for targeting this cascade.](#)

Chapter 02

[Figure 2.1 A 59-year-old female with history of left oophorectomy for ovarian mucinous adenocarcinoma, presenting with left-pelvic mass consistent with](#)

recurrent disease. (a-c): Axial T2 (a), axial T1 with fat saturation (b), and axial T1 post-contrast with fat saturation (c) MRI images demonstrate a lobulated cystic lesion with enhancing internal septations within the left adnexa (yellow arrows). (d,e): Axial and coronal T2-weighted MRI images demonstrate that the mass causes left-ureteral obstruction and left hydronephrosis (blue arrows).

Figure 2.2 A 57-year-old female with mucinous adenocarcinoma/pseudomyxoma peritonei, status post-appendectomy, TAH/BSO, and multiple debulking surgeries. (a) Axial T2-weighted image with fat saturation demonstrates a lobulated cystic mass within the posterior pelvis (blue arrow) consistent with recurrent disease. Ascites with nodularity noted within the pelvis (yellow arrow). (b) Coronal T2-weighted image demonstrates upper abdominal ascites with a soft tissue noted below the right hemidiaphragm, consistent with metastatic implant (yellow arrow).

Figure 2.3 A 58-year-old female with history of endometrial carcinoma and large right-adnexal mass seen on CT (ovarian clear cell carcinoma). (a) Axial T2-weighted image demonstrates a spiculated T2-hypointense mass within the right adnexa (yellow arrow). (b) Coronal T2-weighted image with fat saturation demonstrates again the T2-hypointense right-adnexal mass (yellow arrow), with pelvic ascites and a T2-hypointense metastatic peritoneal soft tissue deposit (blue arrow). (c, d): Axial pre- (c) and post-contrast (d) T1-weighted images demonstrate a T1-hypointense right-adnexal mass with heterogeneous enhancement following intravenous contrast administration (yellow arrow).

Figure 2.4 A 44-year-old female with ovarian endometriosis, bilateral ovarian lesions and elevated CA-125 (endometriosis-associated ovarian cancer). (a) Axial T2-weighted MR image demonstrates a mixed cystic and solid left-ovarian mass (yellow arrow). (b) Axial T2-weighted MR image demonstrates a T2-hypointense lesion within the right ovary (blue arrow). (c) Axial T1-weighted MR image with fat saturation demonstrates that the right-ovarian lesion is also T1-hyperintense, consistent with hemorrhage and the patient's known ovarian endometrioma (blue arrow). The left-ovarian mixed cystic and solid mass is also seen (yellow arrow). (d) Axial T1-weighted post-contrast MR image with fat saturation demonstrates the enhancement of the solid components of the left-ovarian mass (yellow arrow).

Figure 2.5 A 35-year-old female presenting with amenorrhea and elevated testosterone, with left-adnexal mass seen on ultrasound (sex-cord stromal tumor—Leydig tumor). (a) Axial T2-weighted image demonstrates a heterogeneous solid mass within the left adnexa (yellow arrow), as well as a small amount of fluid within the pelvis. (b) Axial T1-weighted MR image demonstrates enhancement of the mass following intravenous contrast (yellow arrow). (c,d) Axial T1-weighted in- and out-of-phase images demonstrate that the left-adnexal mass loses signal intensity on out-of-phase images, demonstrating the presence of microscopic lipid within the lesion (yellow arrows). This is a described feature of sex-cord stromal tumors.

Figure 2.6 A 61-year-old female with uterine carcinosarcoma. (a-c): Axial (a), sagittal (b), and coronal (c) contrast-enhanced CT images demonstrate a heterogeneously enhancing mass

within the uterus, which distends the endometrial cavity, consistent with the patient's known tumor (yellow arrow).

Figure 2.7 A 93-year-old female with postmenopausal bleeding and thickened endometrium (carcinosarcoma of the uterus). (a) Ultrasound of the pelvis with color Doppler demonstrates hypervascular mass within the endometrium (yellow arrow). (b). Axial T2-weighted image demonstrates a heterogeneous mass within the uterus (yellow arrow). (c) Axial post-contrast T1-weighted image demonstrates heterogeneous enhancement of the uterine mass (yellow arrow), with a large nonenhancing necrotic portion (blue arrow). (d) Axial PET-CT images demonstrate that the uterine mass is markedly hypermetabolic (yellow arrow), with the necrotic portion again seen (blue arrow). (e) Whole-body-infused PET CT image demonstrates diffuse metastatic disease (representative lesions highlighted with green arrows).

Figure 2.8 An 81-year-old female with right-adnexal mass (carcinosarcoma of the fallopian tube). (a) CT scan of the pelvis demonstrates a right-adnexal mass, which is inseparable from the ovary (yellow arrow). (b) Axial T2-weighted MR image demonstrates a mixed cystic and solid mass within the right adnexa, which appears separate from the right ovary that is seen anteriorly (yellow arrow).

Figure 2.9 A 45-year-old female with palpable pelvic mass, heavy vaginal bleeding for several months, and fungating necrotic mass seen within the vagina on pelvic exam (uterine leiomyosarcoma). Axial (a) and coronal (b) contrast-enhanced CT images demonstrate a heterogeneously enhancing mass

within the uterus (*yellow arrows*). Note heterogeneous low-density tissue within the vagina, corresponding to necrotic mass seen on physical examination (*blue arrow*).

Figure 2.10 A 60-year-old female with metastatic uterine leiomyosarcoma. (a,b) Axial contrast enhanced CT images demonstrate a low density left-retroperitoneal mass causing left hydronephrosis (*yellow arrows*), consistent with metastatic disease. Note is made of a left-nephroureteral stent. (c) Axial CT image through the lower thorax demonstrates multiple pulmonary nodules of varying size, consistent with pulmonary metastatic disease (*blue arrows*).

Figure 2.11 A 28-year-old female with history of molar pregnancy, status post-dilatation and curettage, with elevated and rising hCG (metastatic choriocarcinoma). (a,b) Coronal (a) and sagittal (b) images from intravenous and oral contrast-enhanced CT demonstrates a hypervascular enhancing mass within the uterus (*yellow arrows*). (c) Axial image of the chest demonstrates multiple pulmonary nodules of varying size, consistent with metastatic disease (*blue arrows*).

Figure 2.12 A 19-year-old female with metastatic melanoma involving the vagina. (a-d): Coronal (a) and axial (b-d) contrast-enhanced CT images demonstrate a heterogeneously enhancing mass within the vagina (*blue arrow*), as well as multiple other enhancing masses within chest and abdomen, including the right kidney, left-anterior abdominal wall, right axilla, mediastinum, and lungs, consistent with metastatic melanoma (*yellow arrows*).

Figure 3.1 Retiform Sertoli-Leydig cell tumor. The biphasic pattern with neoplastic epithelium and stroma can cause *this tumor to be misinterpreted as a malignant mixed mesodermal tumor (carcinosarcoma)*. That the tumor illustrated was from a 12-year-old should cause a distinctive tumor of the young to be considered.

Figure 3.2 Small cell carcinoma of the ovary, hypercalcemic type. Although one of the most malignant tumors of the ovary this neoplasm is not particularly pleomorphic, although obviously malignant with brisk mitotic activity.

Figure 3.3 Metastatic malignant melanoma in the ovary. The presence of spaces simulating follicles and the abundant eosinophilic cytoplasm may cause a juvenile granulosa cell tumor to be entertained.

Figure 3.4 High-grade squamous cell carcinoma arising in dermoid cyst. The great majority of this tumor was an undifferentiated large cell malignant tumor and only focal squamous differentiation prompted further sampling, which disclosed minor foci of residual dermoid cyst.

Figure 3.5 Endometrioid carcinoma simulating sex cord tumor. The nests at the bottom left, in isolation, would be consistent with granulosa cell tumor, but this well-sampled tumor shows additionally obvious neoplastic endometrioid glands ruling out a sex cord tumor.

Figure 3.6 Large solitary luteinized follicle cyst of pregnancy and the puerperium. If this large unilocular cystic mass was not known to be associated with pregnancy, a diagnosis of cystic granulosa cell tumor would be reasonable.

Figure 3.7 Clear cell adenocarcinoma. Typical papillary pattern.

Figure 3.8 Struma ovarii with clear cells. A clear cell carcinoma was strongly considered because of the clear cells and the colloid material was originally overlooked. Immunohistochemical stains for thyroglobulin were strongly positive.

Figure 3.9 Serous papillary tumor of borderline malignancy. Hobnail cells are conspicuous and may cause potential confusion with a clear cell carcinoma.

Figure 3.10 Juvenile granulosa cell tumor. A few of the follicles are lined by hobnail cells, and if the follicles are considered cysts, the combination with hobnail cells may erroneously suggest clear cell carcinoma. That the patient was a child is obviously helpful.

Figure 3.11 Metastatic renal cell carcinoma to ovary. Although resembling primary clear cell carcinoma because of the presence of tubules and clear cells, there are many other differences between these two tumors.

Figure 3.12 Yolk sac (endodermal sinus) tumor. A Schiller-Duval body, the papillary formation with a central blood vessel, is seen at the left, and the typical reticular pattern of yolk sac tumor is seen at the right. Schiller-Duval bodies are an overemphasized feature of this tumor, often being absent.

Figure 3.13 Carcinoid tumor of ovary. Sometimes the acini of this neoplasm are dilated and can simulate glands of well-differentiated adenocarcinoma. There is an eosinophilic hue to the cytoplasm suggesting the presence of neuroendocrine granules.

Figure 3.14 Small cell carcinoma of ovary, hypercalcemic type, large cell variant. Despite its name, about 40% of these tumors have cells that are large with abundant eosinophilic cytoplasm, enhancing the diagnostic challenges associated with this entity.

Chapter 04

Figure 4.1 Ovarian clear cell carcinoma within an endometriotic cyst. Typical gross appearance of a polypoid mass with focal brownish discoloration of the cyst lining (top right).

Figure 4.2 Ovarian clear cell carcinoma demonstrating the classic tubulocystic pattern.

Figure 4.3 Ovarian clear cell carcinoma. Papillary pattern showing stromal hyalinization is a typical feature of the papillae in many clear cell carcinomas.

Figure 4.4 Ovarian clear cell carcinoma with a typical admixture of patterns. A minor tubulocystic component (top right) coexists with a dominant nodular growth of cells with clear cytoplasm (lower left).

Chapter 06

Figure 6.1 Pseudomyxoma peritonei involving the omentum 50 × Hematoxylin and Eosin.

Figure 6.2 Pseudomyxoma peritonei involving the omentum 100 × Hematoxylin and Eosin.

Figure 6.3 Pseudomyxoma peritonei involving the ovary 12.5 × Hematoxylin and Eosin.

Chapter 07

Figure 7.1 Keratin pearl formation can be a frequent finding. Squamous cell carcinoma can develop from

malignant degeneration of squamous elements within mature cystic teratomas.

Figure 7.2 Direct involvement of endometriosis in a squamous cell carcinoma of the ovary.

Figure 7.3 Squamous metaplasia with subsequent malignant change of the columnar epithelium.

Figure 7.4 Reprinted with permission from Ref. [43]. © Springer.

Figure 7.5 Reprinted with permission from Ref. [43]. © Springer.

Chapter 12

Figure 12.1 Small cell carcinoma of hypercalcemic type. The presence of follicles on a background more or less diffuse growth of small cells is characteristic.

Figure 12.2 Small cell carcinoma of hypercalcemic type. High-power view showing typical small cells with scant cytoplasm. Despite the highly malignant nature of the lesion, pleomorphism is not striking. The mitotic rate is, however, brisk.

Figure 12.3 Small cell carcinoma of pulmonary type. Large areas of necrosis on a background of a highly malignant small cell carcinoma of the common type seen in the lung are typical. Note the different low-power appearances from the hypercalcemic-type tumor which is an unrelated neoplasm.

Chapter 13

Figure 13.1 Primary ovarian insular carcinoid tumor composed of solid nests and small acini.

Figure 13.2 Primary ovarian trabecular carcinoid tumor composed of long cords or ribbons surrounded by connective tissue.

Figure 13.3 Primary ovarian strumal carcinoid tumor composed of thyroid follicles admixed with carcinoid tumor.

Figure 13.4 Primary ovarian mucinous carcinoid tumor composed of well-formed glands surrounded by connective tissue.

Chapter 14

Figure 14.1 (a) An example of a homologous MMMT with poorly differentiated carcinoma at 400×. (b) An example of a heterologous MMMT with chondrosarcomatous elements at 200×. Both micrographs are courtesy of Dr. Ian Hagemann at Washington University School of Medicine.

Chapter 16

Figure 16.1 Low-power view of mucinous adenocarcinoma of the uterus. Tumor invades superficial myometrium.

Figure 16.2 High-power view showing columnar mucinous cytoplasm of epithelium lining glands.

Chapter 20

Figure 20.1 Neuroendocrine carcinoma of the cervix. Small hyperchromatic cells with scant cytoplasm and typical brisk mitotic activity.

Chapter 22

Figure 22.1 Embryonal rhabdomyosarcoma of the vagina. Characteristic polypoid growth with hypercellular subepithelial region (cambium layer beneath which is deceptively benign-appearing edematous component).

Figure 22.2 High-power view from previous case showing strap cells.

Figure 22.3 Aggressive angiomyxoma. Paucy cellular myxoid neoplasm with typical prominent vascular component.

Uncommon Gynecologic Cancers

Edited by

Marcela G. del Carmen, md, mph

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Robert H. Young, md, frcpath

James Homer Wright Pathology Laboratories

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

John O. Schorge, md

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Michael J. Birrer, md, phd

Department of Medicine

Massachusetts General Hospital
Boston, MA, USA

WILEY Blackwell

This edition first published 2015 © 2015 by John Wiley & Sons, Ltd.

Registered Office

John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex,
PO19 8SQ, UK

Editorial Offices

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should

be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Uncommon gynecologic cancers / edited by Marcela del Carmen, John O. Schorge, Robert H. Young, Michael J. Birrer.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-65535-1 (cloth)

I. Del Carmen, Marcela, editor. II. Schorge, John O., editor. III. Young, Robert H. (Robert Henry), 1950- , editor. IV. Birrer, Michael J., editor.

[DNLM: 1. Genital Neoplasms, Female. WP 145]

RC280.G5 616.99'465-dc23

2014033566

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover images courtesy of Dr Robert H. Young, Massachusetts General Hospital, Boston, MA, USA

Cover design by Meaden Creative

List of Contributors

David M. Boruta, MD

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Leslie S. Bradford, MD

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Cesar M. Castro, MD

Massachusetts General Hospital Cancer Center and
Department of Medicine

Harvard Medical School
Boston, MA, USA

Rachel M. Clark, MD

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Marcela G. del Carmen, MD, MPH

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology

Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Don S. Dizon, MD, FACP

Oncology of Sexual Health

Gillette Center for Gynecologic Oncology

Massachusetts General Hospital Cancer Center
Boston, MA, USA

Amanda Nickles Fader, MD

The Kelly Gynecologic Oncology Service
Johns Hopkins Hospital
Baltimore, MD, USA

Olivia W. Foley, BA

Division of Gynecologic Oncology, Vincent Obstetrics and
Gynecology
Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Rosemary Foster, PhD

Vincent Center for Reproductive Biology
Vincent Department of Obstetrics and Gynecology
Massachusetts General Hospital
Boston, MA, USA

Leslie A. Garrett, MD

Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Beth Israel Deaconess Hospital
Boston, MA, USA

Annekathryn Goodman, MD

Division of Gynecologic Oncology, Vincent Obstetrics and
Gynecology
Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

Whitfield Growdon, MD

Vincent Center for Reproductive Biology
Vincent Department of Obstetrics and Gynecology
Massachusetts General Hospital
Boston, MA, USA

Ariel A. Kaphan

Massachusetts General Hospital Cancer Center and
Department of Medicine, Harvard Medical School,
Boston, MA, USA